137 related articles for article (PubMed ID: 19879382)
1. Deregulated signalling networks in human brain tumours.
Grzmil M; Hemmings BA
Biochim Biophys Acta; 2010 Mar; 1804(3):476-83. PubMed ID: 19879382
[TBL] [Abstract][Full Text] [Related]
2. Targeting multiple kinases in glioblastoma multiforme.
Sathornsumetee S; Reardon DA
Expert Opin Investig Drugs; 2009 Mar; 18(3):277-92. PubMed ID: 19243279
[TBL] [Abstract][Full Text] [Related]
3. Molecular pathways and potential therapeutic targets in glioblastoma multiforme.
Wardak Z; Choe KS
Expert Rev Anticancer Ther; 2013 Nov; 13(11):1307-18. PubMed ID: 24168050
[TBL] [Abstract][Full Text] [Related]
4. Receptor Tyrosine Kinase Signaling and Targeting in Glioblastoma Multiforme.
Tilak M; Holborn J; New LA; Lalonde J; Jones N
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33673213
[TBL] [Abstract][Full Text] [Related]
5. Targeting Protein Kinases for the Treatment of Glioblastoma Multiforme: Linking Basic Studies to Clinical Applications.
Zhou A
Curr Pharm Des; 2017 Nov; 23(29):4290-4302. PubMed ID: 28699529
[TBL] [Abstract][Full Text] [Related]
6. Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets.
Mao H; Lebrun DG; Yang J; Zhu VF; Li M
Cancer Invest; 2012 Jan; 30(1):48-56. PubMed ID: 22236189
[TBL] [Abstract][Full Text] [Related]
7. Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice.
Lee C; Fotovati A; Triscott J; Chen J; Venugopal C; Singhal A; Dunham C; Kerr JM; Verreault M; Yip S; Wakimoto H; Jones C; Jayanthan A; Narendran A; Singh SK; Dunn SE
Stem Cells; 2012 Jun; 30(6):1064-75. PubMed ID: 22415968
[TBL] [Abstract][Full Text] [Related]
8. Incorporating molecular tools into early-stage clinical trials.
Weil RJ
PLoS Med; 2008 Jan; 5(1):e21. PubMed ID: 18215108
[TBL] [Abstract][Full Text] [Related]
9. Glycogen synthase kinase-3β (GSK-3β) and its dysregulation in glioblastoma multiforme.
Atkins RJ; Stylli SS; Luwor RB; Kaye AH; Hovens CM
J Clin Neurosci; 2013 Sep; 20(9):1185-92. PubMed ID: 23768967
[TBL] [Abstract][Full Text] [Related]
10. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice.
Holland EC; Celestino J; Dai C; Schaefer L; Sawaya RE; Fuller GN
Nat Genet; 2000 May; 25(1):55-7. PubMed ID: 10802656
[TBL] [Abstract][Full Text] [Related]
11. Meningiomas, dicentric chromosomes, gliomas, and telomerase activity.
Carroll T; Maltby E; Brock I; Royds J; Timperley W; Jellinek D
J Pathol; 1999 Aug; 188(4):395-9. PubMed ID: 10440750
[TBL] [Abstract][Full Text] [Related]
12. Role of mTOR in glioblastoma.
Duzgun Z; Eroglu Z; Biray Avci C
Gene; 2016 Jan; 575(2 Pt 1):187-90. PubMed ID: 26341051
[TBL] [Abstract][Full Text] [Related]
13. Targeting DUSPs in glioblastomas - wielding a double-edged sword?
Prabhakar S; Asuthkar S; Lee W; Chigurupati S; Zakharian E; Tsung AJ; Velpula KK
Cell Biol Int; 2014 Feb; 38(2):145-53. PubMed ID: 24155099
[TBL] [Abstract][Full Text] [Related]
14. Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date.
Bastien JI; McNeill KA; Fine HA
Cancer; 2015 Feb; 121(4):502-16. PubMed ID: 25250735
[TBL] [Abstract][Full Text] [Related]
15. Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype.
Choe G; Park JK; Jouben-Steele L; Kremen TJ; Liau LM; Vinters HV; Cloughesy TF; Mischel PS
Clin Cancer Res; 2002 Sep; 8(9):2894-901. PubMed ID: 12231534
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic strategies to target multiple kinases in glioblastoma.
Sathornsumetee S
Anticancer Agents Med Chem; 2011 Oct; 11(8):700-11. PubMed ID: 21707500
[TBL] [Abstract][Full Text] [Related]
17. A Thermodynamic-Based Interpretation of Protein Expression Heterogeneity in Different Glioblastoma Multiforme Tumors Identifies Tumor-Specific Unbalanced Processes.
Kravchenko-Balasha N; Johnson H; White FM; Heath JR; Levine RD
J Phys Chem B; 2016 Jul; 120(26):5990-7. PubMed ID: 27035264
[TBL] [Abstract][Full Text] [Related]
18. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies.
Stommel JM; Kimmelman AC; Ying H; Nabioullin R; Ponugoti AH; Wiedemeyer R; Stegh AH; Bradner JE; Ligon KL; Brennan C; Chin L; DePinho RA
Science; 2007 Oct; 318(5848):287-90. PubMed ID: 17872411
[TBL] [Abstract][Full Text] [Related]
19. Erlotinib: early clinical development in brain cancer.
Addeo R; Zappavigna S; Parlato C; Caraglia M
Expert Opin Investig Drugs; 2014 Jul; 23(7):1027-37. PubMed ID: 24836441
[TBL] [Abstract][Full Text] [Related]
20. Complexities of lysophospholipid signalling in glioblastoma.
Ng W; Pébay A; Drummond K; Burgess A; Kaye AH; Morokoff A
J Clin Neurosci; 2014 Jun; 21(6):893-8. PubMed ID: 24746442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
